2023 World Conference on Lung Cancer (Posters)-EP08.02. Durvalumab as Maintenance in Patients who Received Chemoradiotherapy for Unresectable Stage III NSCLC: RWD from an EAP in Brazil (LACOG 0120)

EP08.02. Durvalumab as Maintenance in Patients who Received Chemoradiotherapy for Unresectable Stage III NSCLC: RWD from an EAP in Brazil (LACOG 0120) - PDF(Abstract)

Back to course

Pdf Summary

This study, conducted in Brazil, aimed to evaluate the efficacy and safety of durvalumab as maintenance therapy in patients with unresectable stage III non-small cell lung cancer (NSCLC) who had received chemoradiotherapy. Durvalumab is an immune checkpoint inhibitor that has been shown to improve overall survival and progression-free survival in this patient population. <br /><br />The study included 31 patients from 7 centers who were treated with durvalumab as part of an Expanded Access Program between September 2017 and June 2018. The patients had completed platinum-based chemotherapy concurrently or sequentially with radiation therapy and did not show evidence of disease progression. <br /><br />The median follow-up duration was 50.3 months, and the median time to start durvalumab after radiation therapy was 56.5 days. Patients received a mean of 17.9 doses of durvalumab over a median of 9.7 months. <br /><br />The results showed that the median progression-free survival was 13.3 months in adenocarcinoma patients and not reached in squamous cell carcinoma patients. The 12-, 24-, and 36-month progression-free survival rates were 46.7%, 39.5%, and 34.6% respectively. The median overall survival was 37.5 months in both adenocarcinoma and squamous cell carcinoma patients. The 12-, 24-, and 36-month overall survival rates were 89.3%, 72.6%, and 46.3%, respectively. <br /><br />The main reasons for discontinuation of durvalumab treatment before 12 months were disease progression, loss to follow-up, and death due to a second primary tumor. Treatment-related adverse events were reported in 38.7% of patients, with pneumonitis occurring in 12.9% of patients. <br /><br />Although the progression-free survival was slightly lower than in the pivotal PACIFIC trial, the overall survival observed in this real-world setting was similar, suggesting the efficacy of durvalumab treatment in Brazilian patients with unresectable stage III NSCLC. No new safety concerns were identified.

Asset Subtitle

Mauro Zukin

Meta Tag

Speaker Mauro Zukin

Topic Local-Regional NSCLC: Multimodality Therapy

Keywords

Brazil

durvalumab

maintenance therapy

unresectable stage III NSCLC

chemoradiotherapy

overall survival

progression-free survival

adenocarcinoma

squamous cell carcinoma

treatment-related adverse events